drugset
drugset / Trial / NCT03828227

QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

NCT03828227 ↗

Phase 3 Active not recruiting 49 enrolled GERCOR - Multidisciplinary Oncology Cooperative Group
RandomizedParallel-groupOpen-labelOther

Summary

A national, multicenter, open-label, randomized phase III study. The trial aim is to determine the best therapeutic strategies according with the HRQoL.

Timeline

Start
2019-06-14
Primary completion
2023-11-10
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Comparator Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Comparator Capecitabine Small molecule 1000 mg/m2 Oral
Comparator Leucovorin Small molecule 400 mg/m2 Intravenous
Comparator Oxaliplatin Small molecule 85 mg/m2 Intravenous
Comparator fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

colorectal cancer